We find that BRAF V600E tumors lack significant synergy (low Bliss excess) but still achieve consistently strong tumor suppression (high GR values) from drug regimens with as low dosing as Belvarafenib 100 mg QD and Cobimetinib 20 mg QD. This evidence concerns the gene BRAF and neoplasm.